Real-world economic burden of hepatitis C and impact of direct-acting antivirals in France: A nationwide claims data analysis.

Laurent LamPatrizia CarrieriGilles HejblumJonathan BelletMarc BourlièreFabrice Carrat

Published in: Liver international : official journal of the International Association for the Study of the Liver (2024)

A significant economic burden persists among patients with HCV infection after DAA treatment. The high proportion of patients not treated with DAA therapy supports reinforcing policies for universal access.

Keyphrases

data analysis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
public health
hepatitis c virus
prognostic factors
health insurance
stem cells
cross sectional
human immunodeficiency virus
patient reported